StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Aquestive Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.89M, down 19.1% year over year. For fiscal 2025 it was $17.19M, down 15.2% from the year before. The highest annual figure on record is $23.11M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.19M-15.2%
FY2024Dec 31, 2024$20.28M+54.8%
FY2023Dec 31, 2023$13.10M-25.0%
FY2022Dec 31, 2022$17.48M+2.5%
FY2021Dec 31, 2021$17.05M-14.3%
FY2020Dec 31, 2020$19.89M-3.3%
FY2019Dec 31, 2019$20.57M-11.0%
FY2018Dec 31, 2018$23.11M+4.4%
FY2017Dec 31, 2017$22.13M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.96M-3.5%
Q1 FY2026Mar 31, 2026$4.20M-21.6%
Q4 FY2025Dec 31, 2025$3.20M-35.0%
Q3 FY2025Sep 30, 2025$4.53M-14.0%
Q2 FY2025Jun 30, 2025$4.11M-1.4%
Q1 FY2025Mar 31, 2025$5.36M-9.6%
Q4 FY2024Dec 31, 2024$4.92M+70.3%
Q3 FY2024Sep 30, 2024$5.27M+64.9%
Q2 FY2024Jun 30, 2024$4.16M+19.8%
Q1 FY2024Mar 31, 2024$5.93M+67.2%
Q4 FY2023Dec 31, 2023$2.89M-32.5%
Q3 FY2023Sep 30, 2023$3.20M-1.1%
Q2 FY2023Jun 30, 2023$3.47M-33.2%
Q1 FY2023Mar 31, 2023$3.55M-25.7%
Q4 FY2022Dec 31, 2022$4.28M-2.8%
Q3 FY2022Sep 30, 2022$3.23M-31.6%
Q2 FY2022Jun 30, 2022$5.20M+22.0%
Q1 FY2022Mar 31, 2022$4.77M+30.4%
Q4 FY2021Dec 31, 2021$4.40M-0.6%
Q3 FY2021Sep 30, 2021$4.73M-34.9%
Q2 FY2021Jun 30, 2021$4.26M+10.8%
Q1 FY2021Mar 31, 2021$3.66M-16.0%
Q4 FY2020Dec 31, 2020$4.43M+44.7%
Q3 FY2020Sep 30, 2020$7.26M+43.4%
Q2 FY2020Jun 30, 2020$3.85M-52.8%
Q1 FY2020Mar 31, 2020$4.35M+1.2%
Q4 FY2019Dec 31, 2019$3.06M-46.2%
Q3 FY2019Sep 30, 2019$5.06M+3.3%
Q2 FY2019Jun 30, 2019$8.15M+30.0%
Q1 FY2019Mar 31, 2019$4.30M-24.3%
Q4 FY2018Dec 31, 2018$5.68M+17.5%
Q1 FY2018Mar 31, 2018$4.90M–
Q4 FY2017Dec 31, 2017$6.27M–
Q3 FY2017Sep 30, 2017$5.68M–
Q2 FY2017Jun 30, 2017$4.84M–

More Aquestive Therapeutics figures

See a number that looks wrong?